


REMARKS

Currently claims 1-40 are pending. Applicants amend claims 11-13, 20, 23-24, 28-29, 33-34, and 38-39 to remove unintentional duplication and to reduce the filing fee by, *inter alia*, removing multiple dependency. Claims 4-7, 10, 14, 16-19, 22, 25, 27, 30, 32, 35, 37, and 40 are cancelled as being in a form inappropriate to US practice and to reduce filing fees by reducing the total number of claims. Accordingly, claims 1-3, 8-9, 11-13, 15, 20-21, 23-24, 26, 28-29, 31, 33-34, 36, and 38-39 are presented for examination. Applicants amend the specification for purposes of adding the priority information. The attached Abstract has been placed on a separate sheet of paper according to US practice.

Respectfully submitted,



John L. Lemanowicz
Attorney for Applicant
Registration No. 37,380

Date: 20 Jan 2005
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8247
Facsimile: 919-483-7988